← Leaderboards
Michael E Hurwitz
Massachusetts General Hospital
$948,881
Attributed
$1,218,172
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $303.7K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,218,172 · 2
By mechanism
K08$679,590 · 1
R21$538,582 · 1
Top collaborators
- Samuel G Katz4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Loren M Frank$13,127,500
- Joren C Madsen$70,026,219
- Rajesh T Gandhi$16,079,023
- Hensin Tsao$3,663,046
- Anna Mandinova$4,254,717
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellGenesCellsPhenotypeMalignant NeoplasmsProgramsPathway InteractionsProteinsEfficacy EvaluationInfrastructureInterleukin-2Infusion ProceduresDoseEffector T CellIn VitroGenerationsApoptoticClinical TrialsGene TherapyCell ReprogrammingCell Differentiation ProcessAntitumor ResponseImmunotherapyExperimental Study
Grant awards (9)
Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming$185,977
R21 · FY2024 · CA
Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming$84,638
R21 · FY2024 · CA
Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming$33,048
R21 · FY2024 · CA
Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming$234,919
R21 · FY2023 · CA
Screening of Synthetic Lethality with C. elegans Rb$136,080
K08 · FY2008 · CA · contact PI
Screening of Synthetic Lethality with C. elegans Rb$136,080
K08 · FY2007 · CA · contact PI
Screening of Synthetic Lethality with C. elegans Rb$136,080
K08 · FY2006 · CA · contact PI
Screening of Synthetic Lethality with C. elegans Rb$136,080
K08 · FY2005 · CA
Screening of Synthetic Lethality with C. elegans Rb$135,270
K08 · FY2004 · CA